DFX Intelligence
Private Credit Intelligence
The capital structure graph behind private markets. Who lent, to whom, under which sponsor, through which facility, how large the piece was, when it matures and what changed, with a filing behind every number. A BDC piece is that BDC's piece, a sum of pieces is a lower bound, and a sponsor is named with the evidence that names it.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Borrower
R••••••• B••••••••• I••
Drug Discovery & Developmentgroup grade Aon a schedule nowsponsor unattributed
Principal held
unknown
sum of BDC pieces, a lower bound
Fair value
$16,000
n/a on cost, debt pieces
Unfunded
n/a
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
1 equity pieces beside them
Next maturity
unstated
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Jun 30, 2026
Events
1
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Jun 30, 2024 | at least $4.4M | 100c | S+425 bp | Jan 1, 2026 | 1 |
Equity pieces beside the debt: preferred equity ($16,000 fair value, 1 BDC)
Lenders
every BDC piece at the latest quarter end
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | preferred equity equity Warrant, 3/23/2022, Preferred Series E | n/a | $16,000 80c |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $0 | $0 | n/a | 0 |
| Mar 31, 2026 | 1 | $0 | $0 | n/a | 0 |
| Dec 31, 2025 | 1 | $0 | $0 | n/a | 0 |
| Sep 30, 2025 | 1 | $0 | $0 | n/a | 0 |
| Jun 30, 2025 | 1 | $0 | $0 | n/a | 0 |
| Mar 31, 2025 | 1 | $0 | $0 | n/a | 0 |
| Dec 31, 2024 | 1 | $0 | $0 | n/a | 0 |
| Sep 30, 2024 | 1 | $0 | $0 | n/a | 0 |
| Jun 30, 2024 | 1 | $4.4M | $4.5M | 100c | 0 |
| Mar 31, 2024 | 1 | $5.0M | $5.1M | 101c | 0 |
| Dec 31, 2023 | 1 | $10.0M | $10.2M | 101c | 0 |
| Sep 30, 2023 | 1 | $5.0M | $5.1M | 101c | 0 |
| Jun 30, 2023 | 1 | $5.0M | $5.0M | 101c | 0 |
| Mar 31, 2023 | 1 | $5.0M | $5.0M | 100c | 0 |
| Dec 31, 2022 | 1 | $5.0M | $4.9M | 100c | 0 |
What changed
- Facility left every BDC scheduleJun 30, 2024
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- REDSHIFT BIOANALYTICSderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it